What is SPG4?
What is HSP SPG4?
Hereditary spastic paraplegia type 4 (SPG4) is the most common autosomal dominant form of hereditary spastic paraplegia, caused by pathogenic variants in the SPAST gene. SPAST encodes spastin, a microtubule severing ATPase that plays a central role in maintaining axonal cytoskeletal dynamics, intracellular transport, and endosomal trafficking. Loss of normal spastin function leads to impaired microtubule turnover and accumulation of disorganized cytoskeletal structures, particularly in long corticospinal tract neurons. Clinically, this manifests as a length dependent axonopathy characterized by progressive lower extremity spasticity, hyperreflexia, and weakness, with onset ranging from infancy to late adulthood. Certain variants, including missense mutations such as Arg499His, are thought to exert dominant negative effects, further disrupting microtubule regulation beyond simple haploinsufficiency.
At the cellular level, SPG4 is increasingly understood as a disorder of axonal maintenance rather than development. Dysfunctional spastin leads to impaired axonal transport, defective organelle distribution (including mitochondria and endosomes), and progressive distal axonal degeneration. The selective vulnerability of long motor neurons, particularly those innervating the lower limbs, reflects the high dependence of these cells on efficient microtubule mediated transport over extended distances. Emerging data also suggest roles for spastin in endoplasmic reticulum shaping and lipid droplet dynamics, further implicating broader disruptions in neuronal homeostasis. These insights have shifted the field toward targeting intracellular trafficking and cytoskeletal integrity as core therapeutic entry points.
Current therapeutic research in SPG4 is focused on three principal strategies: gene modulation, gene replacement, and gene editing. Antisense oligonucleotides (ASOs) are being explored to modulate SPAST expression, particularly in cases of dominant negative mutations, where selective suppression of mutant transcripts may be beneficial. Adeno associated virus (AAV) mediated gene therapy aims to restore functional spastin through delivery of a healthy SPAST transgene, although challenges remain regarding dosage control, cell type specificity, and achieving sufficient distribution across the central nervous system. Gene editing approaches, including CRISPR based systems, offer the theoretical advantage of directly correcting pathogenic variants at the DNA level, but remain limited by delivery constraints, off target risks, and the need for highly efficient editing in post mitotic neurons.
Across these approaches, the central challenge is not simply restoring spastin levels, but reversing or stabilizing an established axonal pathology. This includes addressing accumulated microtubule disorganization and downstream degenerative changes that may not be fully reversible once established. As a result, there is increasing emphasis on early intervention, development of sensitive biomarkers, and improved natural history studies to define therapeutic windows. The field is also actively investigating combinatorial strategies, such as pairing gene based therapies with agents that enhance microtubule stability or axonal transport, to maximize functional recovery. Ultimately, the goal is to transition from symptomatic management toward disease modifying therapies that can halt or meaningfully slow progression, particularly in early onset and more aggressive phenotypes.
